A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse.
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Aim: Testing the addition of I-MIBG or Crizotinib to intensive therapy in children and adults with high-risk neuroblastoma (NBL).
Aim: To analyze biomarkers in tumor tissue samples from patients with newly diagnosed Neuroblastoma or Ganglioneuroblastoma.
Aim: A study of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones.
Aim: A study to compare the addition of Blinatumomab in combination with chemotherapy in patients diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B‑ALL and the treatment of patients with localized B-cell Lymphoblastic Lymphoma (B-LLy).
Aim: A study to test if the addition of Inotuzumab Ozogamicin (InO) to standard chemotherapy treatment in patients diagnosed with National Cancer Institute (NCI) High-Risk (HR) B-cell Acute Lymphoblastic Leukemia (B-ALL) or NCI Standard-Risk (SR) BALL with high risk features improves outcomes.
The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study. Aim: A childhood cancer registry of infants, children, adolescents, and young adults with cancer called Project: EveryChild, which supports current and future therapeutic clinical trials and the discovery efforts that will lead to more effective therapies, prevention, earlier…
A prospective survey of the patients’ understanding on genetic tests for cancer genetic syndromes.
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS).